Press release Third quarter 2021

Issued: Wednesday, 27 October 2021, London, U.K. 3 Operating performance – Q3 2021 Turnover Q3 2021 £m Growth £% Growth CER% Pharmaceuticals 4,397 5 10 Vaccines 2,174 7 13 Consumer Healthcare 2,506 3 8 Group turnover 9,077 5 10 Group turnover was £9,077 million in the quarter, up 5% AER, 10% CER.

  October, 27 october

Emma Walmsley, CEO - gsk.com

Agenda 2 Q2 2018 progress (15 mins) Emma Walmsley, Chief Executive Officer Q2 2018 financial results (15 mins) Simon Dingemans, Chief Financial Officer

  Mame

Audit & Risk Committee Terms of Reference - Home | GSK

Audit & Risk Committee – Terms of Reference 2 3. Each of the members of the Committee shall be independent Non-Executive Directors, as determined by the Board of the Company, in accordance with the provisions of the UK Corporate

  Terms, Risks, Reference, Committees, Audit, Terms of reference audit amp risk committee

Q3 2021 results

Progressing towards demerger at pace. 8. 1. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. 2021-26 CAGR is for the 5 …

Annual Report 2018 - GSK

GSK Annual Report 2018 02. Research & development . Success in R&D will always be fundamental to shareholder returns. A renewed focus on R&D was set out by Emma Walmsley when she became CEO in 2017, and a new plan to improve the pipeline of new medicines has now been launched by Dr Hal Barron, our new Chief

  Annual, Report, 2018, 2018 annual report, Gsk annual report 2018

Press release Full year and fourth quarter 2020 - GSK

* Reported AER and CER growth rates for 2020 include five months’ results of the former Pfizer consumer healthcare business in 2019. Pro-forma CER growth rates are calculated as if the equivalent seven months of Pfizer consumer healthcare business results, as reported by Pfizer, were included in the comparative period of 2019.

  Pfizer

Annual Report 2019 - GSK

Trust We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. Our values and expectations Our values – patient focus, transparency, respect and integrity. Our expectations – courage, accountability, development and teamwork.

  Trust, Annual, Report, Annual report, Affordable

Financial statements - GSK

The Group financial statements for the year ended . 31 December 2020, comprising principal statements and supporting notes, are set out in the ‘Financial statements’ on pages 154 to 237 of this report. The parent company financial statements for the year ended 31 December 2020, comprising the balance sheet and the statement of changes in

  Testament, Financial, Financial statements

Annual Report 2020 - GSK

framework, we invest in our business to provide shareholder returns. In 2020 we paid a dividend of 80p per share and delivered £5.4 billion of free cash flow. We make a positive contribution to the communities in . which we operate. We employ over 94,000 people across 96 countries and work directly with 36,000 suppliers.

  Annual, Report, Return, 2200, Shareholders, 2002 annual report, Shareholder returns

Press release Second quarter 2021

All expectations, guidance and targets regarding future performance and dividend payments should be read together with ‘Outlook, assumptions and cautionary statements’ on pages 68 and 69. If exchange rates were to hold at the closing rates on 30 June 2021 ($1.39/£1, €1.17/£1 and Yen 153/£1) for the rest of 2021, the

  Dividend, And dividends

Access to medicines: making market forces serve the poor

Global Strategy and Plan of Action on Public Health, Innovation and Intellectual ... pharmaceutical industry is a business, and a big one. Multinational pharmaceutical companies, ... would stimulate efforts to get prices down through policies such as tiered pricing, voluntary and compulsory licensing, pooled procurement, and bulk purchasing. ...

  Pharmaceutical, Global, Policies, Pricing

NEW DRUG LISTING & PRICING POLICIES IN CHINA

pricing for “premium-priced” drugs, the majority of which are manufactured by multi-national companies (MNCs). For the first time, the Ministry has begun to consider pharmacoeconomic and budget-impact evidence in its decision-making, signaling the need for global companies to approach the Chinese market differently in future.

  Drug, Global, Chain, Policies, Listing, Pricing, New drug listing amp pricing policies in china

Glosario de términos farmaceuticos / Glossary of ...

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies medicamentos con un uso médico bien establecido para el cual ningún producto de referencia está disponible en la UE. 2) Extensiones de la marca registrada a nivel nacional de medicamentos para los que una información armonizada del producto

  Pharmaceutical, Policies, Pricing, Pharmaceutical pricing

MEDICINES REIMBURSEMENT POLICIES IN EUROPE

authorities included in the Pharmaceutical Pricing and Reimbursement Information (PPRI) network, a literature review, qualitative interviews with authorities and researchers in selected case study countries, and a cross-country analysis of the actual financial burden for patients.

  Pharmaceutical, Policies, Reimbursement, Medicine, Europe, Pricing, Pharmaceutical pricing, Medicines reimbursement policies in europe

Economic Survey 2021-22

160 Global Inflation 161 Domestic Inflation 162 Current Trends in Inflation and its Drivers 188 Housing Prices 193 Pharmaceutical Pricing 194 Long Term Perspective for Management of Supply Side Factors 6 Sustainable Development and Climate Change 197 India’s Progress on Sustainable Development Goals 203 State of the Environment

  Pharmaceutical, Global, Pricing, Pharmaceutical pricing

MARKET INSIGHT Biopharmaceutical CDMOs Analysis

The global biologics market is expected to account for ~30% of the entire pharma market by 2025 compared to 18.5% in 2015. In the ten year span from 2015 to 2025, the global biologics CDMO market is projected to grow at an average annual growth rate of 15.1% from $7.4b n to $30.3bn. 1

  Analysis, Global, Market, Insights, Biopharmaceutical, Dcom, Market insight biopharmaceutical cdmos analysis

EFFECTS OF INNOVATION TYPES ON FIRM PERFORMANCE - …

1 EFFECTS OF INNOVATION TYPES ON FIRM PERFORMANCE Gurhan GUNDAY a, Gunduz ULUSOY a,*, Kemal KILIC a, Lutfihak ALPKAN b a Sabanci University, Faculty of Engineering and Natural Sciences, 34956 Orhanli-Tuzla, Istanbul, Turkey b Gebze Institute of Technology, Department of Management, No:101 41400 Cayirova Gebze-Kocaeli, Turkey E-mail addresses: …